EP0125269A1 - Composes pharmaceutiquement actifs - Google Patents

Composes pharmaceutiquement actifs

Info

Publication number
EP0125269A1
EP0125269A1 EP19830903560 EP83903560A EP0125269A1 EP 0125269 A1 EP0125269 A1 EP 0125269A1 EP 19830903560 EP19830903560 EP 19830903560 EP 83903560 A EP83903560 A EP 83903560A EP 0125269 A1 EP0125269 A1 EP 0125269A1
Authority
EP
European Patent Office
Prior art keywords
derivative according
group
glycoprotein
derivative
hydrolysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19830903560
Other languages
German (de)
English (en)
Inventor
Richard Anthony Godwin Smith
Jeffery Hugh Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0125269A1 publication Critical patent/EP0125269A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to enzyme derivatives for use in the treatment of thrombotic diseases.
  • European Published Patent Application No. 0,009,879 discloses derivatives of in vivo fibrinolytic enzymes which are useful therapeutic agents for treating venous thrombosis.
  • the derivatives are characterised by the active catalytic site on the enzymes being blocked by a group which is removable by hydrolysis such that the pseudo-first order rate constant for hydrolysis is in the range 10 -6 sec -1 to 10 -3 sec -1 .
  • fibrinolytically active glycoproteins can be modified by removal or degradation of the carbohydrate portion of the protein and subsequently blocked by a removable group, to produce derivatives having surprisingly slow physiological clearance rates and prolonged in vivo stability.
  • the term 'fibrinolytically active glycoprotein' means any glycoprotein which demonstrates jLn. vivo fibrinolytic activity as defined in the above mentioned published European Patent Application, and includes glycoproteins which are obtainable from mammalian urine, blood or tissues or by recombinant DNA methods and which can activate plasminogen. Examples of these include melanoma plasminogen activator, the extraction of which is described in Published European Patent Application No, 41766, and urokinase.
  • a derivative of a fibrinolytically active glycoprotein in which at least part of the carbohydrate portion of the protein is absent or has been degraded characterised in that the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis at a rate such that the pseudo- first order rate constant for hydrolysis is in the range 10 ⁇ 6 sec ⁇ "l to 10 ⁇ 3 to sec ⁇ "l in isotonic aqueous media at pH 7.4 at 37oc.
  • Preferred glycoproteins are tissue activators, such as melanoma plasminogen activator, and urokinase, and preferably substantially all the carbohydrate in the glycoprotein is removed or degraded.
  • Suitable blocking groups are those described in Published European Patent Application No. 0 009 879, and preferred groups are acyl groups, particularly optionally substituted benzoyl groups.
  • the most preferred benzoyl groups are those substituted with a basic moiety, such as amino or guanidino.
  • the pseudo-first order rate constant is determined by hydrolysing the glycoprotein derivative under physiological conditions ie. in isotonic aqueous media at pH 7.4 and at 37°C. At regular intervals aliquots are withdrawn and incubated with a chromogenic or fluorogenic protease substrate such as S-2444 for urokinase or S-2288 for tissue activators and the rate of conversion of the substrate measured.
  • a max is the maximum rate at which an aliquot converts substrate and A t is the rate at which an aliquot converts substrate at time t.
  • the derivatives of this invention may be prepared by,
  • step (b) of the preparation can be carried out first, and the resulting blocked glycoprotein can then be subjected to the modification process of step (a).
  • Step (a) of the above preparation may be carried out in various ways, but preferred methods are as follows: i) Chemical degradation of carbohydrate units utilising, for example, sodium periodate. This method of degradation is based on published procedures (Biochem. Biophys. Res. Commun., 57, 55, 1974).
  • glycosidases selected for example from ⁇ -galactosidase, ⁇ -mannosidase, ⁇ -fucosidase, ⁇ -N-acetylglucosaminidase or neuraminidase, or one or more endoglycosidases, such as endoglycosidase D (from Diplococcus pneumoniae) or endoglycosidase H (from Streptomyces plicatus).
  • the glycosidases may be immobilised on insoluble carriers to avoid contamination of the modified glycoprotein.
  • melanoma plasminogen activator preparation from cultured melanoma cells grown in the presence of an inhibitor of protein glycosylation, such as tunicamycin.
  • Step (b) of the preparation is preferably carried out by reacting the modified glycoprotein from step (a) with a blocking agent
  • A is a locating group which locates the agent in the catalytic site
  • B is an acyl group.
  • B is a 2- or 4-aminobenzoyl group otionally substituted in the aromatic ring by an electron donating moiety.
  • Preferred examples of the group A include 4-amidinophenyl, 2-nitro 4-amidinophenyl and 4-acetamidinophenyl or structurally similar substituted phenyl groups containing a positively charged moiety in the 3- or 4- position.
  • Preferred agents AB are 4-aminophenyl-4'aminobenzoate and 4-aminophenyl-2'-aminobenzoate.
  • the blocking reactions are preferably carried out in aqueous media at a pH range which is not detrimental to the glycoprotein, blocking agent or product, eg between pH 5 and 9 and preferably at a pH in the range 6.0 to 8.0.
  • the reaction is generally carried out using a molar excess of blocking agent, but equi-molar equivalents may also be employed. It is also preferred to carry out the reaction in dilute solution, ie less than 10 -3 molar with respect to glycoprotein and less than 10 -2 molar with respect to blocking agent. Generally the reaction will not be carried out in a solution where the concentration of glycoprotein or blocking agent is less than 10 -7 molar.
  • the blocking reaction should be carried out at moderate temperatures, ie room temperature or below, and more particularly less then 10°C but greater than the freezing point of the reaction medium.
  • A is 4-amidinophenyl
  • a suitable protecting group is the tertiary-butoxycarbonyl (BOC) group.
  • BOC tertiary-butoxycarbonyl
  • the reaction is preferably carried out in a tertiary organic base, such as pyridine, and in the presence of a condensation promoting agent such as dicyclohexyl carbodiimide. If desired, the condensation reaction may also be carried out without prior protection of the amino group.
  • the N-protection of the aminobenzoic acid material is preferably carried out by treating the material with ditertiary butyl dicarbonate.
  • the de-protection of the product is suitably carried out by treating the product with TFA (trif ⁇ uoroacetic acid), preferably at room temperature.
  • the derivative of this invention is preferably administered as a pharmaceutical compostion.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the derivative of the invention in combination with a pharmaceutically acceptable carrier.
  • the compositions according to the invention may be formulated in accordance with routine procedures as pharmaceutical compositions adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions of the sterile derivative in sterile isotonic aqueous buffer.
  • the composition may also include a solubilising agent to keep the derivative in solution and a local anaesthetic such as lignocaine to ease pain at the site of injection.
  • the derivative will be supplied in unit dosage form for example, as a dry powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of glycoprotein in activity units, as well as an indication of the time within which the free, modified protein will be liberated.
  • the derivative will be dispensed with an infusion bottle containing sterile pharmaceutical grade 'Water for Injection'.
  • the derivative is to be administered by injection the derivative is dispensed with an ampoule of sterile water for injection.
  • the injectable or infusable composition will be made up by mixing the ingredients prior to administration.
  • the quantity of material administered will depend upon the amount of fibrinolysis required and the speed with which it is required, the seriousness of the thromboembolic condition and position and size of the clot.
  • the precise dose to be employed and mode of administration must per force in view of the nature of the complaint be decided according to the circumstances by the physician supervising treatment.
  • a patient being treated for a mature thrombus will generally receive a daily dose of from 0.10 to 2.0 mg/kg -1 of body weight either by injection in up to five doses or by infusion.
  • a method of treating thrombotic diseases which comprises administering to the sufferer an effective non-toxic amount of the derivative of the invention.
  • pre-dose i ⁇ mediately post-dose and 10, 20, 30, 45, 60, 90, 120, and 180 minutes post-dose.
  • Fibrin plates were prepared from 0.4% w/v human fibrinogen (KabiVitrum, Sweden) in 0.05 M sodium barbitone 0.45% w/v NaCl pH 7.4 (10ml) on 10 x 10 cm square plastic dishes, clotting with bovine throiribin (c. 10 NIH units, Parke-Davis, UK) . Plates were incubated at 26°C for 16-18 hr (occasionally longer if zones of lysis did not develop adequately) and stained with aqueous Bromophenol Blue. Zones of lysis were measured with Vernier calipers and the area calculated from the mean of perpendicular diameters. b) Assay of fibrinolytic activity in the bloodstream of rats
  • mice Male Sprague-Dawley rats (300-400 g) were anaesthetized with pentobarbitone sodium (60 mg/kg i.p.). One carotid artery was cannulated for collection of blood samples. One femoral vein was cannulated for injection of heparin (50 U/kg) and compound under test. Approximately 5 min after heparinization, a pre-dose blood sample (0.8 ml) was taken and mixed with 0.1 volumes 129 mM trisodium citrate. The compound under test was then injected (1 ml/kg) over 10s. Further blood samples were taken exactly 1, 2, 4, 8, 16, 30 and 60 min later.
  • Heparin treatment 50 U/kg was repeated after the 30 min sample to maintain cannula patency. All citrated blood samples were kept on ice until the end of each experiment, then centrifuged at 1700 g for 15 min at 4o to obtain plasma. The euglohulin fraction was precipitated by adding 0.1 ml each plasma to 1.82 mL ice-cold 0.011% (v/v) acetic acid in water. After 30 min standing in ice, all tubes were centrifuged at 1700 g for 15 min at 4°.
  • Fibrin plates were prepared from 0.4% (w/v) human fibrinogen (Kabi, Grade L, Flow Laboratories, Scotland) dissolved in 0.029 M barbitone in 125 mM NaCl, pH 7.4, pipetted (9 ml) into 10 x 10 cm square plastic dishes (Sterilin) and clotted by rapid mixing with 0.3 ml bovine thrombin (50 NIH units/ml, Parke-Davis, UK) . Plates were incubated at 37° for 18-24h usually, but longer if required, and stained with aqueous bromophenol blue. For each lysis zone, two diameters perpendicular to each other were ireasured using Vernier calipers.
  • Urokinase (Abbokinase, Abbott Laboratories, USA) with a molecular weight of approximately 33,000 daltons (2 vials, 5 x 10 5 international units) was dissolved in 0.1 M sodium phosphate, 0.145 M NaCl, 0.01% Tween 80, pH 6.0 (1.0 ml). The solution was gel filtered into the same buffer in order to remove excipient mannitol. A small column (PD 10, Pharmacia, Sweden) of Sephadex G-25 M was used and the protein eluate volume was 3.0 ml. 2.0 ml or this eluate was treated with 0.2 ml of freshly prepared 0.1 M sodium periodate in water for 70 min on ice in the dark.
  • the reaction mixture was quenched with 0.2 ml glycerol for 30 min on ice, followed by neat ethanolamine (2.5 ⁇ l).
  • the above gel filtration was repeated and the activity of the eluate was measured spectrophotometrically using the chromogenic substrate S-2444 (Kabi Vitrum, Sweden, 0.25 mM in 0.1 M triethanolamine. HCl pH 8.0, 25°C) and the recovery of amidolytic activity was 37.5%.
  • This eluate (1.5 ml) was treated with 4-aminobenzoic acid 4'-amidinophenyl ester HCl (15 ⁇ l of a 100 mM solution in dimethyl sulphoxide) for 30 min at ambient temperature (c. 25oC).
  • the amidolytic activity of the product indicated that the enzyme was at least 98% acylated.
  • FIG. 1 shows the time dependence of fibrin plate lysis following doses of: (1) unmodified urokinase; (2) urokinase modified only by acylation; (3) urokinase modified only by periodate oxidation; (4) doubly modified urokinase (AP/POLUK). Five animals were used in each group. The figure shows that the clearance of at least part of the doubly modified enzyme is appreciably slower than that of either unmodified or singly modified urokinases.
  • Example 2 shows that the clearance of at least part of the doubly modified enzyme is appreciably slower than that of either unmodified or singly modified urokinases.
  • Urokinase (Abbokinase, Abbott Laboratories, USA, 2.5 x 10 5 international units) was dissolved in 0.1 M triethanolamine HCl pH 8.0 (1.0 ml) and treated with 0.5 mM 4-aminobenzoic acid 4'-amidihophenyl ester HCl for 4 hr on ice, after which time acylation was essentially complete as judged by amidolytic assay with S-2444 (see above). The solution was gel filtered as described in Example 1 into 0.1 M sodium phosphate 0.145 M NaCl 0.01% Tween 80 pH 6.0 (3.0 ml). 1.0 ml of this solution was retained and the remaining 20 ml treated with sodium periodate as described in Example 1.
  • Urokinase (Serono Pharmaceuticals, Germany) with a molecular weight of 54,000 daltons (3 x 10 units) was dissolved in 2.5 ml of 0.1 M sodium phosphate, 0.01% Tween 80, pH 6.0 and gel filtered into 3.0 ml of the same buffer as described in Example 1. 2.0 ml of the eluate was treated with sodium periodate as described in Example 1 except that oxidation was carried out for 90 min on ice. Quenching and gel filtration were performed as described in Example 1 and amidolytic assay (S-2444) indicated an activity recovery of 56%. The final eluate (1.5 ml) was treated with 1.0 mM 4-aminobenzoic acid 4'- amidinophenyl ester. HCl for lh at 0°C. Amidolytic assay indicated essentially complete acylation and the preparation was stored at -40oC.
  • Human tissue plasminogen activator (TPA) was obtained from the culture filtrate of Bowes melanoma cells and was purified to 70-90% homogeneity by standard chromatographic procedures. The activator was dissolved in 0.1 M sodium phosphate, 0.145 M NaCl, 0.01% Tween 80, pH 6.0 to a concentration of 0.5-1.0 mg/ml. Oxidation with sodium periodate and subsequent quenching and gel filtration were carried out as described in Example 1 except that oxidation was performed at 4oC for 1 hr. Enzyme activity was measured using substrate S-2288 (Kabi Vitrum, Sweden) under the conditions described for S-2444.
  • TPA Human tissue plasminogen activator
  • oxidation enzyme activity dropped to 70% of initial but returned to 100% of initial after-treatment with glycerol and ethanolamine.
  • the eluate was bought to pH 8.0 by addition of 1/10th of the volume of 1.0 M trishydroxyrnethylaminomethane and 4-aminobenzoic acid 4'-aminobenzoic acid HCl (50 mM in dimethylsulphoxide) added to a final concentration of 1.0 mM.
  • acylation was essentially complete and excess acylating agent was removed by gel filtration as previously described.
  • the potential enzyme activity in the acyl-enzyme was checked by allowing a portion of the final eluate to deacylate at pH 7.5 for 16 hr and 25oC and measuring the activity using S-2288.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un dérivé d'une glycoprotéine fibrinolytiquement active, dans laquelle au moins une partie de l'hydrate de carbone de la protéine est absente ou a été dégradée se caractérise en ce que le site catalytique essentiel à l'activité fibrinolytique est bloqué par un groupe qui est amovible par hydrolyse à une vitesse telle que la constante de vitesse de pseudo-premier ordre pour l'hydrolyse se trouve dans la plage comprise entre 10-6sec-1 et 10-3sec-1 dans un milieu aqueux isotonique à un pH de 7,4 à 34oC. Le dérivé est utile dans le traitement des thromboses.
EP19830903560 1982-11-11 1983-11-10 Composes pharmaceutiquement actifs Withdrawn EP0125269A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8232228 1982-11-11
GB8232228 1982-11-11

Publications (1)

Publication Number Publication Date
EP0125269A1 true EP0125269A1 (fr) 1984-11-21

Family

ID=10534195

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19830903560 Withdrawn EP0125269A1 (fr) 1982-11-11 1983-11-10 Composes pharmaceutiquement actifs

Country Status (2)

Country Link
EP (1) EP0125269A1 (fr)
WO (1) WO1984001960A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
US5073494A (en) * 1985-04-22 1991-12-17 Genentech, Inc. Human tissue plasminogen activator substituted at position 275 or at positions 275 and 277
IE81073B1 (en) * 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
US5589361A (en) * 1986-03-18 1996-12-31 Genentech, Inc. Human tissue-type plasminogen activator variant
US5217705A (en) * 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
US5346824A (en) * 1988-05-20 1994-09-13 Genentech, Inc. DNA encoding variants of tissue plasminogen activators and expression vectors and hosts thereof
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5156969A (en) * 1988-09-02 1992-10-20 Genentech Inc. Tissue plasminogen activator variant with deletion of amino acids 466-470 having fibrin specific properties
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
DE10199044I2 (de) * 1992-06-03 2006-02-09 Genentech Inc Varianten des Gewebeplasminogenaktivators mit verbesserter Therapeutischer wirkung
US5474766A (en) * 1992-12-18 1995-12-12 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
EP0028489B1 (fr) * 1979-11-05 1983-10-05 Beecham Group Plc Dérivés d'enzymes et leur préparation
US4326033A (en) * 1980-05-05 1982-04-20 Abbott Laboratories Modified urokinase having extended activity and method of making
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8401960A1 *

Also Published As

Publication number Publication date
WO1984001960A1 (fr) 1984-05-24

Similar Documents

Publication Publication Date Title
US4908204A (en) Reversibly blocked plasmin, t-PA hybrid fibrinolytic enzymes and pharmaceutical compositions and anti-thrombotic use thereof
AU596356B2 (en) Novel human tissue plasminogen activator mutants
WO1984001786A1 (fr) Derives d'enzymes et leur utilisation dans le traitement de la thrombose
US4970159A (en) Human tissue plasminogen activator consisting essentially of t-PA residues 160 to 527
EP0125269A1 (fr) Composes pharmaceutiquement actifs
JPH05304957A (ja) 酵素誘導体、それらの製造法およびそれらを含有する医薬組成物
US5753224A (en) Hybrid protein C
EP0233013A2 (fr) Enzyme modifié
US4604285A (en) Protein C enzyme derivatives
CA2071630C (fr) Proteine c hybride
US4507283A (en) Pharmacologically active compounds
EP0290118A2 (fr) Enzyme d'activité fibrinolytique
US4999194A (en) Two-chain urokinase plasminogen activators for treatment of thrombotic disease
CA2145749C (fr) Derives du plasminogene activables par la thrombine
EP0250071A1 (fr) Enzymes fibrinolytiques, leurs procédés de préparation et leur utilisation
US5234686A (en) Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
CA2086835C (fr) Variants d'activateur tissulaire du plasminogene a clairance reduite
US4880776A (en) Plasmin A-chain urokinase B-chain hybrid protein
EP0336508A1 (fr) Mutant recombinant d'une urokinase du type activateur du plasminogène constitué d'une seule chaîne et produite par une mutagénèse remplaçant la lysine 158 par de l'histidine
EP0292326A2 (fr) Enzyme modifié
EP0535037A1 (fr) Activateurs de plasminogene hybrides
EP0277751A2 (fr) Enzyme fibrinocytique modifie
JPS60174727A (ja) 新規なプラスミノ−ゲン・アクチベ−タ−の安定化方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): CH DE FR GB LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19841016

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROBINSON, JEFFERY, HUGH

Inventor name: SMITH, RICHARD, ANTHONY, GODWIN